weight loss center semaglutide and Tirzepatide for Elevate your weight loss journey

Salty snacks are seeing a slight decline but werent on the list of top products experiencing spending reductions from GLP-1 users, said Sally Lyons Wyatt, Circanas global executive vice president and chief adviser, Consumer Goods & Foodservice Insights

Both are GLP-1 receptor agonists (tirzepatide also has GIP agonist effects), and they can cause some side effects

These results revealed not only an average weight reduction of as much as 15.7% but an array of equally astonishing secondary outcomes, reaffirming the medications position as the top weight reduction medication on the market

JSS is supported by the Diabetes Research Institute Foundation